Verdiva starts up with $411M and a portfolio of obesity drugs from China
The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...
Outsourcing-pharma8h
Verdiva Bio launches with $411m in funds to advance oral and injectable drugs for obesity
Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...
GlobalData on MSN11h
UK-based Verdiva launches with $410m and an oral GLP-1RA candidate
Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...
pharmaphorum11h
Verdiva Bio raises $411m for obesity pipeline
Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...
pharmaphorum23h
Freenome raises $254m for cancer tests, and other financings
New investors in the round included Nextech Invest, T Rowe Price Associates, Janus Henderson Investors, RA Capital Management, OrbiMed, Surveyor Capital, Medicxi, Logos Capital, Octagon Capital ...